A large pharmaceutical company is trying to determine whether a drug aptly named Recall-Pro can increase your short-term memory capacity. The company prepares a double-blind study as follows: Step 1: A randomly selected pool of individuals is brought to a clinic and is evaluated for any existing health conditions that may impair the results of this experiment. Step 2: The remaining individuals are split into two groups: a treatment group and a control group. Step 3: The control group receives a placebo, but neither the researcher nor the individuals know this. Step 4: The treatment group receives Recall-Pro, but neither the researcher nor the individuals know this. Which step is flawed in the double-blind study? Why? A.Step 1; health screening should not eliminate participants from the study B.Step 2; it does not specify whether the two groups are chosen randomly C.Step 3; the control group does not receive the placebo D.Step 4; members of the treatment group should know that they have received the medication

(1) Answers

The best answer to the question that is being stated above would be letter B. Step 2 is the one that is flawed in the double-blind study because it does not specify that the two groups were randomly chosen. It is important to assign the participants randomly so that the results give a non-confounded result.

Add answer